HALO
Halozyme Therapeutics·NASDAQ
--
--(--)
--
--(--)
HALO fundamentals
Halozyme Therapeutics (HALO) released its earnings on Feb 17, 2026: revenue was 451.77M (YoY +51.60%), beat estimates; EPS was -0.24 (YoY -119.05%), missed estimates.
Revenue / YoY
451.77M
+51.60%
EPS / YoY
-0.24
-119.05%
Report date
Feb 17, 2026
HALO Earnings Call Summary for Q4,2025
- Record Revenue Growth: 2025 total revenue $1.4B (+38%), royalty $868M (+52%). 2026 guidance: $1.71-1.81B revenue, $1.13-1.17B royalty.
- Blockbuster Momentum: DARZALEX SC sales $14.4B, VYVGART Hytrulo $4.15B. 2028 projections: DARZALEX $18B, PHESGO $3.6B.
- Strategic Expansion: 2025 acquisitions add Hypercon tech; 2026 pipeline expands to 15 products with 6 new Phase I starts.
- Innovative Opportunities: ENHANZE ADC data shows 75% lower Cmax vs IV; 2026 Phase I starts for Hypercon in approved drugs.
- Financial Strength: 2025 non-GAAP EPS $4.15, 2026 target $7.75-8.25. Debt/EBITDA <1x by end-2026.
EPS
Actual | -0.04 | 0.19 | 0.25 | 0.5 | 0.19 | 0.62 | 1.48 | 0.46 | 0.43 | 0.16 | 0.44 | 0.42 | 0.47 | 0.74 | 0.75 | 0.82 | 0.79 | 0.91 | 1.27 | 1.26 | 1.11 | 1.54 | 1.72 | -0.24 | |||||||||||
Forecast | -0.0208 | 0.2462 | 0.1947 | 0.5287 | 0.3178 | 0.4349 | 0.4235 | 0.3847 | 0.4613 | 0.47 | 0.3617 | 0.2987 | 0.3825 | 0.63 | 0.7062 | 0.825 | 0.6865 | 0.7586 | 0.9913 | 1.1583 | 0.9484 | 1.2683 | 1.6302 | 2.16 | |||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -92.31% | -22.83% | +28.40% | -5.43% | -40.21% | +42.56% | +249.47% | +19.57% | -6.79% | -65.96% | +21.65% | +40.61% | +22.88% | +17.46% | +6.20% | -0.61% | +15.08% | +19.96% | +28.11% | +8.78% | +17.04% | +21.42% | +5.51% | -111.11% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 25.35M | 55.22M | 65.32M | 121.70M | 89.02M | 136.46M | 115.83M | 102.00M | 117.28M | 152.37M | 208.98M | 181.50M | 162.14M | 221.04M | 216.03M | 230.04M | 195.88M | 231.35M | 290.08M | 298.01M | 264.86M | 325.72M | 354.26M | 451.77M |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 42.96M | 66.68M | 59.90M | 120.01M | 84.88M | 104.12M | 105.84M | 101.54M | 128.25M | 138.63M | 191.17M | 192.05M | 179.26M | 199.95M | 216.08M | 231.00M | 199.74M | 204.94M | 252.17M | 285.74M | 230.11M | 285.91M | 340.03M | 435.71M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -40.99% | -17.18% | +9.04% | +1.41% | +4.88% | +31.06% | +9.44% | +0.46% | -8.56% | +9.91% | +9.31% | -5.50% | -9.55% | +10.55% | -0.02% | -0.42% | -1.93% | +12.89% | +15.03% | +4.29% | +15.10% | +13.92% | +4.19% | +3.69% |
Earnings Call
You can ask Aime
What guidance did Halozyme Therapeutics's management provide for the next earnings period?What were the key takeaways from Halozyme Therapeutics's earnings call?What were the key takeaways from Halozyme Therapeutics’s earnings call?What is the revenue and EPS growth rate for Halozyme Therapeutics year over year?Did Halozyme Therapeutics beat or miss consensus estimates last quarter?What does Halozyme Therapeutics do and what are its main business segments?What factors drove the changes in Halozyme Therapeutics's revenue and profit?What is Halozyme Therapeutics's latest dividend and current dividend yield?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
